News | February 17, 2025
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
No safety signals related to the vaccine candidate were identified
No safety signals related to the vaccine candidate were identified
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Approval is based on positive data from the Phase 3 ECHELON-3 trial
TFOS is indicated for the treatment of pulmonary arterial hypertension
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Cancer cases in India estimated to reach 1.57 million in 2025
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Subscribe To Our Newsletter & Stay Updated
